PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Anti-cancer drug price regulation in India: Financial implications and annual savings to patients

Disparities in myeloma: Closing the gap

Long-term outcomes and complications in cancer patients who have recovered from COVID-19

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa

OncoAlert and ecancer - ESMO 2021 preview

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients

Should every transplant eligible NDMM patient receive a transplant?

Vaccinations in myeloma patients including for COVID-19

Culture, Community and Communication in Advanced Disease in India